Saturday, July 11, 2026

Drug profile · INN

paramethasone acetate

paramethasone acetate (HALDRONE) is a glucocorticoid receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — paramethasone acetate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

paramethasone acetate (HALDRONE) is a glucocorticoid receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN paramethasone acetate
Brand HALDRONE
Mechanism Glucocorticoid receptor agonist
Target Glucocorticoid receptor
Route ORAL
Formulation TABLET

Mechanism of action

Glucocorticoid receptor agonist

Primary target: Glucocorticoid receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. beclomethasone dipropionate Glucocorticoid receptor agonist
  2. betamethasone acetate Glucocorticoid receptor agonist
  3. betamethasone dipropionate Glucocorticoid receptor agonist
  4. betamethasone valerate Glucocorticoid receptor agonist
  5. budesonide Alimentary tract and metabolism (A07)
  6. clobetasol propionate Glucocorticoid receptor agonist

Frequently asked questions

What is paramethasone acetate?

paramethasone acetate (HALDRONE) is a glucocorticoid receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for paramethasone acetate?

HALDRONE is a marketed brand name for paramethasone acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of paramethasone acetate?

paramethasone acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.